What we do
MRI of liver & pancreas
Mangafodipir returns as a manganese-based contrast agent with a safer profile for MRI.
Mangafodipir was previously marketed by GE Healthcare under the trade name Teslascan™ as a contrast agent for diagnostic MRI for the detection of focal lesions of the liver and the pancreas. Teslascan™ was withdrawn from the market for commercial reasons prior to the emergence of safety concerns with gadolinium-based contrast agents (GBCAs).
GBCAs improve the diagnostic capabilities of magnetic resonance imaging and have been used for more than 30 years. However, GBCAs can cause nephrogenic systemic fibrosis (NSF) when used in patients with kidney disease. Retention of gadolinium in the brain and other organs was detected with increased exposure to GBCAs. Therefore, the marketing authorisation for some GBCAs was suspended, and the use of some GBCAs restricted to prevent any risks that could be associated with gadolinium deposition in the brain.
Manganese-based contrast agents are a safe alternative to existing GBCAs and have the potential to replace gadolinium-based imaging.
IC Targets is currently establishing manufacturing and supply chain resources for mangafodipir, aiming to apply for marketing authorisation in the EU and the US, and to re-launch mangafodipir for the detection of focal lesions of the liver and the pancreas.